<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03571659</url>
  </required_header>
  <id_info>
    <org_study_id>LVPEI-2018</org_study_id>
    <nct_id>NCT03571659</nct_id>
  </id_info>
  <brief_title>Comparison of Different Fluence Settings for Yellow Subthreshold Laser Treatment in Diabetic Macular Edema</brief_title>
  <official_title>To Assess the Safety and Efficacy of Two Subthreshold Parameters (5% and 15% Duty Cycle (DC)) Compared to Standard ETDRS (Early Treatment of Diabetic Retinopathy Study) Continuous Wave (CW) Laser</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>L.V. Prasad Eye Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>L.V. Prasad Eye Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety and efficacy of two subthreshold parameters (5% and 15% duty cycle (DC))
      compared to standard ETDRS (early treatment of diabetic retinopathy study) continuous wave
      (CW) laser
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Test burn up to barely visible burn with micropulse laser, then reduce the power by 70% and
      perform laser with various DC (5%, 15%, cw) as per the group.

      Focal to Mas+ confluent burns to areas of diffuse leakage
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 22, 2014</start_date>
  <completion_date type="Actual">August 11, 2015</completion_date>
  <primary_completion_date type="Actual">December 22, 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>1. Decrease in number of leaking Mas on FFA 2. Decrease in diffuse leakage on FFA</measure>
    <time_frame>3 months</time_frame>
    <description>Comparing the number of leaking microaneuyrms baseline to 6 weeks with 3 types of lasers (two subthreshold parameters (5% and 15% duty cycle (DC)) compared to standard ETDRS continuous wave (CW) laser.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">32</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>two subthreshold parameters</arm_group_label>
    <description>5% and 15% duty cycle (DC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard ETDRS</arm_group_label>
    <description>early treatment of diabetic retinopathy study</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laser</intervention_name>
    <arm_group_label>standard ETDRS</arm_group_label>
    <arm_group_label>two subthreshold parameters</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Asian
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eyes with DME (center or non-center involving) with &lt;350 microns central retinal
             thickness

        Exclusion Criteria:

          -  Subfoveal exudates, history of VR surgery, history of macular laser
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>May 18, 2018</study_first_submitted>
  <study_first_submitted_qc>June 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2018</study_first_posted>
  <last_update_submitted>June 18, 2018</last_update_submitted>
  <last_update_submitted_qc>June 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>L.V. Prasad Eye Institute</investigator_affiliation>
    <investigator_full_name>Dr Jay Chhablani</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

